JP2013525440A - 男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用 - Google Patents

男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用 Download PDF

Info

Publication number
JP2013525440A
JP2013525440A JP2013508147A JP2013508147A JP2013525440A JP 2013525440 A JP2013525440 A JP 2013525440A JP 2013508147 A JP2013508147 A JP 2013508147A JP 2013508147 A JP2013508147 A JP 2013508147A JP 2013525440 A JP2013525440 A JP 2013525440A
Authority
JP
Japan
Prior art keywords
balsalazide
effective amount
therapeutically effective
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013508147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525440A5 (cg-RX-API-DMAC7.html
Inventor
ウィリアム フォーブス
エノク ボーティー
ローリン ジョンソン
Original Assignee
サリックス ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44861888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013525440(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サリックス ファーマシューティカルズ リミテッド filed Critical サリックス ファーマシューティカルズ リミテッド
Publication of JP2013525440A publication Critical patent/JP2013525440A/ja
Publication of JP2013525440A5 publication Critical patent/JP2013525440A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2013508147A 2010-04-26 2011-04-26 男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用 Pending JP2013525440A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32815110P 2010-04-26 2010-04-26
US61/328,151 2010-04-26
PCT/US2011/033905 WO2011137103A1 (en) 2010-04-26 2011-04-26 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Publications (2)

Publication Number Publication Date
JP2013525440A true JP2013525440A (ja) 2013-06-20
JP2013525440A5 JP2013525440A5 (cg-RX-API-DMAC7.html) 2014-06-19

Family

ID=44861888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508147A Pending JP2013525440A (ja) 2010-04-26 2011-04-26 男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用

Country Status (9)

Country Link
US (3) US8497256B2 (cg-RX-API-DMAC7.html)
EP (1) EP2563117B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013525440A (cg-RX-API-DMAC7.html)
AU (1) AU2011245455A1 (cg-RX-API-DMAC7.html)
BR (2) BR122014009845A2 (cg-RX-API-DMAC7.html)
CA (1) CA2797560A1 (cg-RX-API-DMAC7.html)
IL (1) IL222642A0 (cg-RX-API-DMAC7.html)
MX (1) MX358142B (cg-RX-API-DMAC7.html)
WO (1) WO2011137103A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236772A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of autoimmune disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506067A (ja) * 2005-08-24 2009-02-12 サリックス ファーマシューティカルズ， インコーポレイテッド バルサラジドの製剤ならびにその製造および使用
JP2010509326A (ja) * 2006-11-03 2010-03-25 サリックス ファーマシューティカルズ， インコーポレイテッド ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US326364A (en) 1885-09-15 Electric-lamp hanger
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
WO1989003219A1 (en) 1987-10-12 1989-04-20 Borody Thomas J Improved method for treatment of gastrointestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US5905073A (en) 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
SE9700934D0 (sv) 1997-03-14 1997-03-14 Astra Ab New formulation
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
CA2285923C (en) 1997-04-01 2013-03-12 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2008033125A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506067A (ja) * 2005-08-24 2009-02-12 サリックス ファーマシューティカルズ， インコーポレイテッド バルサラジドの製剤ならびにその製造および使用
JP2010509326A (ja) * 2006-11-03 2010-03-25 サリックス ファーマシューティカルズ， インコーポレイテッド ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5013006910; ＡＬＥＸＡＮＤＥＲ: 'ＤＩＧＥＳＴＩＶＥ　ＤＩＳＥＡＳＥ　ＷＥＥＫ　ＡＮＤ　ＡＭＥＲＩＣＡＮ　ＤＩＡＢＥＴＥＳ　ＡＳＳＯＣＩＡＴＩＯＮ' ＰＨＡＲＭＡＣＥＹ　ＡＮＤ　ＴＨＥＲＡＰＥＵＴＩＣＳ Ｖ３３　Ｎ９, 2008, Ｐ５４６-５４９ *

Also Published As

Publication number Publication date
EP2563117A4 (en) 2013-09-04
AU2011245455A1 (en) 2012-11-15
US20130295178A1 (en) 2013-11-07
US20150132381A1 (en) 2015-05-14
MX2012012324A (es) 2013-01-29
BR112012027520A2 (pt) 2015-09-15
EP2563117B1 (en) 2018-02-21
US8497256B2 (en) 2013-07-30
IL222642A0 (en) 2012-12-31
EP2563117A1 (en) 2013-03-06
CA2797560A1 (en) 2011-11-03
BR122014009845A2 (pt) 2015-12-29
WO2011137103A1 (en) 2011-11-03
US20120058184A1 (en) 2012-03-08
MX358142B (es) 2018-08-06

Similar Documents

Publication Publication Date Title
JP6067203B2 (ja) ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
US7625884B2 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
CN108289870A (zh) 治疗特定患者群体的神经变性病症的方法
WO2018229133A1 (en) Tinostamustine for use in treating sarcoma
TW202114671A (zh) 包含fxr促效劑之治療
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
JP2013525440A (ja) 男性の治療のための２−ヒドロキシ−５−フェニルアゾ安息香酸誘導体の製剤および使用
HK1182590B (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
HK1182590A (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
AU2013228061B2 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN119280196A (zh) 一种含伐地那非的口溶膜组合物及其应用
JP2013035833A (ja) 頻尿治療用組成物
HK1134221B (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
HK1134221A (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150123

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150930